There was a mistake in Figure 1 as published. In the PDF of the article, the revised version of the Figure was not included. However, it is correct on the webpage. The corrected Figure 1 appears below.
Mechanistic overview of IL-6/STAT3 signaling driving tumor progression and immune evasion in prostate cancer.
Diagram illustrating the role of IL-6/CAF axis in prostate cancer. IL-6 interacts with various cells and pathways, driving immune evasion and therapy resistance. Key components include JAK, STAT, and CAF subtypes, such as iCAF and myCAF. The diagram also indicates the tumor microenvironment involving MDSC and CD8+ T cells, and therapeutic strategies such as IL-6 blockade and IL-6R blockade with agents like Tocilizumab. The effects on neuroendocrine differentiation, endocrine/chemotherapy resistance, and pathways for CAF reprogramming and YAP1 inhibition are highlighted.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland